BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Benzinga · 2d ago
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.